MTNB(Matinas BioPharma Holdings, Inc.) · 财务报表

MTNB(Matinas BioPharma Holdings, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2019-12-31FY 截至 2020-12-31FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31
营业收入$89.81K$158.33K$33.00K$3.19M$1.10M
毛利润—————
营业利润−$18.92M−$24.21M−$24.73M−$24.59M−$23.77M
净利润−$17.37M−$22.45M−$23.28M−$21.00M−$22.94M
经营现金流−$14.09M−$17.37M−$15.22M−$19.16M−$15.28M
自由现金流−$14.50M−$17.37M−$15.48M−$20.05M−$15.50M
摊薄每股收益$-97.50$-90.00$-82.50$-75.00$-79.20

Matinas BioPharma Holdings, Inc. MTNB